TY  - JOUR
AU  - Howe, Anita Y M
AU  - Rodrigo, Chaturaka
AU  - Cunningham, Evan B
AU  - Douglas, Mark W
AU  - Dietz, Julia
AU  - Grebely, Jason
AU  - Popping, Stephanie
AU  - Sfalcin, Javier Alejandro
AU  - Parczewski, Milosz
AU  - Sarrazin, Christoph
AU  - de Salazar, Adolfo
AU  - Fuentes, Ana
AU  - Sayan, Murat
AU  - Quer, Josep
AU  - Kjellin, Midori
AU  - Kileng, Hege
AU  - Mor, Orna
AU  - Lennerstrand, Johan
AU  - Fourati, Slim
AU  - Di Maio, Velia Chiara
AU  - Chulanov, Vladimir
AU  - Pawlotsky, Jean-Michel
AU  - Harrigan, P Richard
AU  - Ceccherini-Silberstein, Francesca
AU  - Garcia, Federico
PY  - 2022
DO  - 10.1016/j.jhepr.2022.100462
UR  - http://hdl.handle.net/10668/22315
T2  - JHEP reports : innovation in hepatology
AB  - Direct-acting antiviral (DAA) regimens provide a cure in >95% of patients with chronic HCV infection. However, in some patients in whom therapy fails, resistance-associated substitutions (RASs) can develop, limiting retreatment options and risking...
LA  - en
PB  - Elsevier BV
KW  - DAA
KW  - DAA, direct-acting antiviral
KW  - DCV, daclatasvir
KW  - DSV, dasabuvir
KW  - GT, genotype
KW  - HCV
KW  - LDV, ledipasvir
KW  - NI, nucleoside
KW  - NNI, non-nucleoside
KW  - NS5A
KW  - NS5AI, NS5A replication complex inhibitor
KW  - OR, odds ratio
KW  - PI, NS3 protease inhibitor
KW  - PIB, pibrentasvir
KW  - RAS
KW  - RASs, resistance-associated substitutions
KW  - SHARED, The Surveillance of Hepatitis C Antiviral Resistance, Epidemiology and methoDologies
KW  - SOF, sofosbuvir
KW  - SVR, sustained virologic response
KW  - VEL, velpatasvir
KW  - aOR, adjusted odds ratio
KW  - sFC, substitution frequency change
KW  - virologic failure
KW  - Humans
KW  - Aged
KW  - Sofosbuvir
KW  - Antiviral Agents
KW  - dasabuvir
KW  - Peptide Hydrolases
KW  - Prevalence
KW  - Metadata
KW  - Hepatitis C, Chronic
KW  - Hepatitis C
KW  - Hepacivirus
KW  - Treatment Failure
KW  - Liver Cirrhosis
KW  - Retreatment
KW  - Genotype
TI  - Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.
TY  - research article
VL  - 4
ER  -